Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E. Brueckl WM, et al. Among authors: schueler a. J Geriatr Oncol. 2023 Jan;14(1):101394. doi: 10.1016/j.jgo.2022.10.009. Epub 2022 Oct 30. J Geriatr Oncol. 2023. PMID: 36323612 Free article.
Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models.
Pantoja K, Lanke S, Munafo A, Victor A, Habermehl C, Schueler A, Venkatakrishnan K, Girard P, Goteti K. Pantoja K, et al. Among authors: schueler a. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1371-1381. doi: 10.1002/psp4.12851. Epub 2022 Aug 5. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35852048 Free PMC article.
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
Fletcher C, Hefting N, Wright M, Bell J, Anzures-Cabrera J, Wright D, Lynggaard H, Schueler A. Fletcher C, et al. Among authors: schueler a. Ther Innov Regul Sci. 2022 Jul;56(4):637-650. doi: 10.1007/s43441-022-00402-3. Epub 2022 Apr 24. Ther Innov Regul Sci. 2022. PMID: 35462609 Free PMC article.
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP. Lebbé C, et al. Among authors: schueler a. Target Oncol. 2021 Jan;16(1):47-57. doi: 10.1007/s11523-020-00767-1. Target Oncol. 2021. PMID: 33211315 Clinical Trial.
41 results